CreosG and Alteogen Sign MOU for Joint Development of Immuno-Oncology Drugs... "Next-Generation Formulation Development"

CreoSG announced on the 6th that it has signed a memorandum of understanding (MOU) with global bio platform company Alteogen for the "development of formulations for immuno-oncology drugs using the Hybrozyme platform technology." Marking the MOU as a starting point, CreoSG plans to accelerate the development of next-generation immuno-oncology drugs and proceed with additional business cooperation with Alteogen.

This MOU centers on the two companies developing formulations optimized for immuno-oncology drugs by utilizing the hyaluronidase 'ALT-B4.' The companies intend to expand the application areas of ALT-B4 through new formulation development and explore joint business opportunities using this technology.

CreoSG plans to apply Alteogen's hyaluronidase technology and expertise to its immuno-oncology drugs under development to enhance the efficacy of immuno-oncology treatments against various cancer types.

Alteogen possesses the hyaluronidase platform 'Hybrozyme (ALT-B4),' which converts intravenous (IV) formulations of antibody drugs into subcutaneous (SC) formulations. Recently, Alteogen signed an exclusive contract with global big pharma Merck (MSD) to convert the world's number one immuno-oncology drug, Keytruda, into an SC formulation. The SC formulation is characterized by greater dosing convenience and fewer side effects from injection compared to the IV formulation.

CreoSG's 'SUV-MAP' is based on the technology of an attenuated recombinant vesicular stomatitis virus (rVSV) that lyses tumors and selectively attacks specific cancer cells, minimizing side effects. In particular, because viral replication is restricted at human body temperature, it offers high safety and can stimulate T cells to induce a strong cellular immune response, functioning as a cancer therapeutic vaccine.

A representative from CreoSG stated, "We have reviewed various cooperation plans to develop immuno-oncology drugs using our proprietary technology and will embark on next-generation immuno-oncology drug development with Alteogen, the top bio platform company in Korea. Based on Alteogen's globally recognized technology and expertise, we will not only expand the application areas of hyaluronidase but also proceed with additional cooperation such as joint new business projects."

He added, "Through synergy between CreoSG's universal new drug development platform and Alteogen's hyaluronidase platform, we will secure differentiated achievements in the immuno-oncology field. We will continue our collaboration with Alteogen to develop immuno-oncology drugs for various cancers including breast, colorectal, pancreatic, and skin cancers, diversifying our new drug pipeline."

CreoSG is expanding its research and development into immuno-oncology drugs based on its proprietary vaccine development technology. To advance SUV-MAP as a platform specialized for immuno-oncology drugs, it recruited an expert in the immuno-oncology field last August and is currently establishing its own immuno-oncology research center.